Neogen (NEOG) Q4 2026 earnings review
Core Growth Accelerates as Supply Chain Woes Reverse
Neogen's Q4 results provide hard evidence that CEO Mike Nassif's turnaround execution is taking hold. Core revenue growth accelerated to 4.3%—the highest rate in FY26—driven by strong momentum in Food Safety (+5.8% core growth). More importantly, the severe supplier disruptions that crushed Animal Safety in Q3 have largely reversed, allowing the segment to return to positive core growth (+0.5%). Adjusted EBITDA margins improved YoY to 20.2%, benefiting from pricing and favorable mix. While Q1 FY27 guidance implies a sequential deceleration due to seasonality, the structural repairs to Neogen's operations appear to be gaining traction.
🐂 Bull Case
The critical Food Safety segment is driving the top line, with Core Growth hitting 5.8%—its highest level since the 3M acquisition in FY23. Bacterial & General Sanitation spiked 9.9% YoY.
Adjusted Gross Margins reached 49.7% (up from 46.4% a year ago). Pricing actions and product mix are effectively overcoming prior operational inefficiencies and tariff headwinds.
🐻 Bear Case
Management's Q1 FY27 guidance of $207-$209M in revenue and ~$37M in Adjusted EBITDA implies a sequential deceleration in margins (dropping to ~17.8%), signaling that profitability remains highly sensitive to seasonal volume.
The $160M Genomics divestiture—crucial for deleveraging the balance sheet—is facing Phase 2 reviews by Australian and New Zealand regulators, introducing timing and completion risks.
⚖️ Verdict: 🟢
Bullish. The data validates management's narrative: core operations are stabilizing, Food Safety is accelerating, and the Q3 Animal Safety collapse was indeed transient. The turnaround is working.
Key Themes
Food Safety Momentum Accelerating
Food Safety was the undisputed growth engine in Q4, generating $166.8M in revenue. The 5.8% core growth rate was driven by structural acceleration in Indicator Testing & Culture Media (+9.5% YoY) and Bacterial & General Sanitation (+9.9% YoY). The implementation of Neogen's new enterprise-wide solutions-based selling model appears to be capturing market share and improving cross-selling.
Animal Safety Supply Chain Reversing
After a disastrous Q3 where Animal Safety core revenue contracted 8.7% due to third-party supplier disruptions (vitamin A shortages, manufacturing transitions), the segment has successfully reversed the trend. Core growth returned to positive territory (+0.5%) in Q4. On a sequential basis, revenue grew 7%, confirming management's prior assertions that the demand was delayed, not destroyed.
Technological Innovation Validated
Neogen's Molecular Detection Assay - Listeria Right Now received AOAC Performance Tested Methods certification. This validates the test's performance for enrichment-free detection of Listeria on stainless steel surfaces. Cutting enrichment times out of the workflow is a significant value proposition for food processors, serving as a distinct commercial driver for FY27.
Rodent and Insect Control Collapsing
While management touted the resolution of Animal Safety supply issues, specific product lines are still severely lagging. Revenue from Rodent Control, Insect Control & Disinfectants within the Animal Safety segment collapsed 22.3% YoY in Q4 to $16.7M (down from $21.5M). This contradicts the broader segment recovery narrative and demands monitoring.
Genomics Divestiture Regulatory Headwinds
The sale of the global Genomics business to Zoetis (expected to yield ~$140M in net proceeds) is facing regulatory friction. The Australian Competition and Consumer Commission (ACCC) and New Zealand Commerce Commission (NZCC) have moved their reviews into a second phase. Any delay in this transaction directly impacts Neogen's ability to execute its planned debt reduction and deleveraging targets for FY27.
Macro Factor: Pest Expansion Acting as Catalyst
In response to the New World Screwworm (NWS) expansion in the United States, Neogen received expanded Federal (FIFRA) Section 2(ee) recommendations for its Prozap Insectrin and Screw Worm products. This provides a tangible, macro-environment tailwind for livestock biosecurity product demand heading into FY27.
Petrifilm Transition Nears Critical Milestones
The highly anticipated internal manufacturing transition for Petrifilm remains on track. The first fully validated single kit unit (SKU) is slated for completion by the end of August 2026, with the multi-quarter manufacturing transition beginning in November 2026. Successfully moving production off the 3M transition agreement is Neogen's largest margin expansion lever for the coming years.
Other KPIs
Accelerating significantly from 46.4% in the prior year quarter. The 330 basis point expansion was driven by a favorable product mix (higher growth in high-margin Food Safety segments) and strategic pricing adjustments. This confirms the new commercial strategy is effectively shielding the bottom line from input cost inflation.
Q4 free cash flow generation was solid, underpinned by $30.2 million in operating cash flow. Full-year operating cash flow improved substantially to $83.2 million from $58.2 million in FY25, highlighting better working capital management and reduced inventory write-offs compared to the previous fiscal year.
Guidance
Stable. Implies approximately 3% core growth when excluding the $6M drag from FY26 Cleaners & Disinfectants revenue and a 1% negative FX headwind. This assumes the Genomics division remains on the books to generate an estimated $92M before the divestiture closes.
Accelerating slightly vs FY26 actuals of $177.8M. The figure includes $13M attributed to the Genomics business. Management expects profitability improvements to scale throughout the year as structural transformation investments begin to yield returns.
Decelerating sequentially from Q4's $225.3M. Management notes that Q1 is typically pressured by seasonality and mix changes. This represents a roughly flat YoY print compared to Q1 FY26 ($209.2M).
Decelerating sequentially. An EBITDA of $37M on ~$208M in sales implies a margin of ~17.8%, a sharp sequential drop from Q4's 20.2% and Q3's 22.8%. Cost disciplines will need to tighten to offset seasonal volume declines.
Key Questions
Genomics Divestiture Risk
With the ACCC and NZCC moving into a Phase 2 review of the Zoetis transaction, what is the contingency plan for deleveraging if the deal is significantly delayed or blocked?
Rodent & Insect Control Weakness
Animal Safety supply issues were largely cited as resolved, yet the Rodent, Insect Control & Disinfectants sub-segment declined over 22% YoY. Are there underlying competitive or demand issues in this specific category separate from the prior supply chain woes?
Margin Seasonality vs Structure
Q1 FY27 guidance implies an adjusted EBITDA margin in the high 17% range, stepping down from the low 20s in the back half of FY26. How much of this is pure seasonality versus reinvestment in the new global go-to-market commercial strategy?